Cost-Effectiveness of iGlarLixi Versus Premix BIAsp 30 in People with Type 2 Diabetes Suboptimally Controlled by Basal Insulin in the US

INTRODUCTION: Many people with type 2 diabetes mellitus (T2DM) experience suboptimal glycemic control and require therapy advancement. This cost-effectiveness analysis was conducted to compare iGlarLixi (insulin glargine 100 U/mL plus lixisenatide) versus BIAsp 30 (biphasic insulin aspart 30) in peo...

Descripción completa

Detalles Bibliográficos
Autores principales: Shao, Hui, Alsaleh, Abdul Jabbar Omar, Dex, Terry, Lew, Elisheva, Fonseca, Vivian
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Healthcare 2022
Materias:
Original Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399315/
https://www.ncbi.nlm.nih.gov/pubmed/35930188
http://dx.doi.org/10.1007/s13300-022-01300-5

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9399315/
https://www.ncbi.nlm.nih.gov/pubmed/35930188
http://dx.doi.org/10.1007/s13300-022-01300-5

Ejemplares similares